« previous next »
Pages: [1]

Author Topic: Higher severe COVID-19 risk for patients on Ocrevus, Rituxan  (Read 57 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9549
  • MS diagnosed 1980
  • Location: Pacific Northwest
Higher severe COVID-19 risk for patients on Ocrevus, Rituxan
« on: July 31, 2020, 07:47:25 am »
From MS Focus (July 24, 2020)--"Higher severe COVID-19 risk for patients on Ocrevus, Rituxan." The article quotes Dr. Ben Thrower, well known in MS research, as saying that the risk of taking MS disease-modifying therapy (DMT) still outweighs the benefits, however.


https://msfocus.org/About-Us/MSF-News-Articles/2279
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9549
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) COVID-19 in ocrelizumab-treated people w/MS
« Reply #1 on: May 03, 2021, 09:46:55 pm »
Might this be a drug company's response to the reports about a higher risk for severe COVID-19 in patients on Ocrevus?  From PubMed, "COVID-19 in ocrelizumab-treated people with multiple sclerosis" (April 2021):


https://pubmed.ncbi.nlm.nih.gov/33482590/
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
97 Views 		Last post December 13, 2018, 09:02:08 pm
by agate
0 Replies
25 Views 		Last post April 07, 2020, 12:07:42 pm
by agate
0 Replies
25 Views 		Last post April 01, 2021, 09:38:48 pm
by agate
0 Replies
31 Views 		Last post September 17, 2021, 08:18:27 pm
by agate
0 Replies
10 Views 		Last post January 07, 2022, 09:48:12 am
by agate